Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

NCT01302847 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

181

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: DTG film-coated tablets
DRUG: DTG granules for suspension
DRUG: DTG dispersible tablets
DRUG: DTG dispersible tablets
DRUG: DTG dispersible tablets

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)